BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis Precision Medicines (NASDAQ:PRAX – Free Report) had its price objective trimmed by Robert W. Baird from $117.00 to $73 ...

Praxis Precision Medicines (PRAX) stock falls amid concerns over success in its late-stage trial for lead asset ulixacaltamide in essential tremor. Read more here.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $132.2, a high estimate of ...

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...

Rezort školstva uvažuje o zmene záverečných prác zavedením alternatívy. Študent by si mohol vybrať buď záverečnú prácu, ...

Needham lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $150 and keeps a Buy rating on the shares. The firm is removing ...

2 market experts have recently issued ratings for this stock, with a consensus target price of $130.5.

Truist lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $175 and keeps a Buy rating on the shares. The firm is removing ...

Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.94 per share versus the Zacks Consensus Estimate of a loss of $2.96. This compares to loss of $2.97 per share a year ago.